AAD

SkinCure Oncology Unveils New Skin Cancer Treatment Technology at American Academy of Dermatology Annual Meeting in San Diego March 8-12 Booth 3555

Retrieved on: 
Thursday, March 7, 2024
Mohs surgery, Cancer, Carcinoma, SRT, Research, Pathology, FDA, Ageing, Food, RCM, Dermatology, Bed, Physiology, Epidermis, Vision, AAD, NMSC, Skin cancer, PAI, Patent, Patient, Tanning, United, American Academy, Medical imaging

GentleView™ is a laser-based imaging device being developed to offer hybrid reflective confocal microscopy and photoacoustic imaging.

Key Points: 
  • GentleView™ is a laser-based imaging device being developed to offer hybrid reflective confocal microscopy and photoacoustic imaging.
  • Reflective confocal microscopy, or RCM, will provide high resolution imaging of the epidermis, to a depth of 200 microns, for cellular level visualization of skin cancer lesions.
  • “SkinCure Oncology,” Brandt continued, “is helping dermatologists nationwide implement the GentleCure Experience – an advanced, noninvasive treatment for NMSC.
  • “Our new devices, subject to FDA Clearance,” Brandt said, “will offer cutting-edge technology in line with SkinCure Oncology’s vision for the future of dermatology.

Alumis Announces Late-Breaker Psoriasis Phase 2 Data Presentation for Allosteric TYK2 Inhibitor ESK-001 at the American Academy of Dermatology 2024 Annual Meeting

Retrieved on: 
Monday, March 4, 2024
SAN, Dermatology, High, Safety, AAD, Patient, Pharmacodynamics, Phase 1, American Academy, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Alumis Inc., a clinical stage biopharmaceutical company developing oral therapies using a precision approach to transform the lives of patients with immune-mediated diseases, today announced two clinical data presentations at the American Academy of Dermatology Annual Meeting taking place March 8-12, 2024, in San Diego, CA.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Alumis Inc., a clinical stage biopharmaceutical company developing oral therapies using a precision approach to transform the lives of patients with immune-mediated diseases, today announced two clinical data presentations at the American Academy of Dermatology Annual Meeting taking place March 8-12, 2024, in San Diego, CA.
  • Details regarding the presentations are as follows:
    Title: Efficacy and Safety of ESK-001, a Highly Selective Oral TYK2 Inhibitor, in a Phase 2 Study in
    Title: Pharmacokinetic and Pharmacodynamic Characteristics of ESK-001, an Oral Allosteric TYK2 Inhibitor, in Phase 1 Healthy Volunteer Trials
    Alumis will also host a virtual investor event to review the ESK-001 Phase 2 clinical data being presented at AAD on March 9 at 5:00 p.m. PT.
  • To access the live webcast, please register by visiting the Events page on the Alumis website.

Sofwave Medical to Present Pure Impact™ Strength and Muscle Toning Module’s First U.S. Industry Reveal at the 2024 American Academy of Dermatology (AAD) Annual Meeting 

Retrieved on: 
Monday, March 4, 2024
SAN, AAD, MHS, American Academy of Dermatology, Dermatology, MD, American Academy

SAN CLEMENTE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, is excited to announce its participation at the 2024 American Academy of Dermatology (AAD) Annual Meeting.

Key Points: 
  • SAN CLEMENTE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, is excited to announce its participation at the 2024 American Academy of Dermatology (AAD) Annual Meeting.
  • Dr. Gilly Munavalli, MD, MHS, FACMS will present Sofwave’s new Pure Impact™ Strength and Muscle Toning module to fellow dermatologists and meeting participants for the first time in the United States.
  • Sofwave Event Detail at AAD:

Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting

Retrieved on: 
Monday, March 4, 2024
Cream, Foam, Doctor of Philosophy, Psoriasis, Randomized controlled trial, MD, Atopic dermatitis, Dermatitis, Itch, AAD, FAAD, Scalp, American Academy

New efficacy and patient-reported outcome data of ZORYVE (roflumilast) topical foam, 0.3%, in seborrheic dermatitis and investigational roflumilast foam in scalp and body psoriasis

Key Points: 
  • New efficacy and patient-reported outcome data of ZORYVE (roflumilast) topical foam, 0.3%, in seborrheic dermatitis and investigational roflumilast foam in scalp and body psoriasis
    WESTLAKE VILLAGE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced five presentations at the 2024 American Academy of Dermatology (AAD) annual meeting, which will take place in San Diego, CA from March 8 - 12, 2024.
  • Among these presentations will be late-breaking clinical data on roflumilast cream 0.05% in patients 2 to 5 years of age with mild to moderate atopic dermatitis from the pivotal INTEGUMENT-PED Phase 3 randomized controlled trial.
  • “Our significant presence at this year’s AAD is a testament to our commitment to bringing meaningful innovation in immuno-dermatology, and building on the body of evidence supporting our topical roflumilast development program.
  • In particular, we are excited to be participating in the late breaking data presentations with new results from INTEGUMENT-PED, as part of our atopic dermatitis clinical program,” said Patrick Burnett, MD, PhD, FAAD, chief medical officer, Arcutis.

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

Retrieved on: 
Monday, March 4, 2024
MIRA, University College Dublin, Doctor of Philosophy, MD, Teaching hospital, Single-domain antibody, EST, Hidradenitis suppurativa, Inflammation, AAD, Safety, Patient, PST, Moonlake, Venereology, HS, American Academy, Pharmaceutical industry

Kristian Reich, MD, PhD, Chief Scientific Officer at MoonLake commented: “We are pleased that the 24-week data from our Phase 2 MIRA trial has been selected by the American Academy of Dermatology as an oral late-breaking presentation.

Key Points: 
  • Kristian Reich, MD, PhD, Chief Scientific Officer at MoonLake commented: “We are pleased that the 24-week data from our Phase 2 MIRA trial has been selected by the American Academy of Dermatology as an oral late-breaking presentation.
  • The presentation will be held on Sunday 10 March at 14:00 PST / 17:00 EST / 23:00 CET during the late breaking research session 2 (S050) in room 20B.
  • Key members of the MoonLake team, including the executive leadership team, will attend AAD.
  • This was followed by an announcement in October 2023, reporting from the trial at 24 weeks, further establishing sonelokimab as a highly promising and differentiated therapeutic solution for HS.

Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting

Retrieved on: 
Thursday, February 29, 2024
Therapy, SAN, Atopic dermatitis, BTLA, Conference, AAD, Webcast, Poster, American Academy, Vaccine

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will participate in a panel discussion at TD Cowen’s 44th Annual Health Care Conference.

Key Points: 
  • SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will participate in a panel discussion at TD Cowen’s 44th Annual Health Care Conference.
  • Additionally, the company announced an upcoming presentation at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, CA, March 8-12, 2024.
  • Date and Time – Tuesday, March 5, 2024 at 2:10pm ET / 11:10am PT
    A live webcast of the panel discussion will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/events .
  • The company’s planned activities are listed below and the full preliminary program is available online on the AAD website.

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

Retrieved on: 
Thursday, February 29, 2024
MIRA, Psoriatic arthritis, EMA, Research, VELA, Medical college, Inflammation, FDA, Investment, Assessment, Conference, AAD, Rheumatology, Event, ARGO, Hidradenitis suppurativa, Webcast, Patient, Science, American Academy, Pharmaceutical industry

Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2023 was another momentous year for MoonLake in the inflammation and immunology field.

Key Points: 
  • Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2023 was another momentous year for MoonLake in the inflammation and immunology field.
  • On top of this, support from world-renowned experts, clinicians, and patient organizations for our data, science and methodologies continues to mount.
  • Matthias Bodenstedt, Chief Financial Officer at MoonLake Immunotherapeutics, said: “MoonLake has added considerable shareholder value over the past year, and we are driven to continue building on this.
  • Other non-operating income increased from $0.6 million in the prior year to $10.1 million for the year ended December 31, 2023.

LEO Pharma Unveils Late-Breaking Data for Landmark DELTA 3 Open-Label Extension Trial at the 2024 AAD Annual Meeting

Retrieved on: 
Saturday, March 9, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Janus, Medicine, AAD, Safety, JAK, COVID-19, Abstract, Patient, CHE, Congress, Disease, LEO, Leo Pharma, American Academy, Pharmaceutical industry

For DELTA 3, subjects who completed the 16-week treatment period in one of the parent trials DELTA 1 and DELTA 2 were treated with twice daily delgocitinib cream as needed to control their chronic hand eczema for 36 weeks.

Key Points: 
  • For DELTA 3, subjects who completed the 16-week treatment period in one of the parent trials DELTA 1 and DELTA 2 were treated with twice daily delgocitinib cream as needed to control their chronic hand eczema for 36 weeks.
  • “Having the opportunity to present the DELTA 3 findings for the first time at AAD is a chance to prove our complete dedication to addressing the immense burden of this disease.
  • By continuing to share our key data at major dermatology congresses, we hope to drive forward the clinical development of delgocitinib cream as a potential new treatment option.”
    Key secondary endpoints demonstrated an efficacy profile consistent with DELTA 1 and 2 parent trials.
  • Alongside the presentation, new data sets at AAD were shared as e-posters from the preceding DELTA 1 and 2 trials regarding safety, efficacy and systemic exposure.2,3,4

LEO Pharma Presents New Long-Term Adbry® (tralokinumab-ldrm) Data in Adults with Moderate-to-Severe Atopic Dermatitis at the 2024 AAD Annual Meeting

Retrieved on: 
Friday, March 8, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, EVP, Atopic dermatitis, ICI, EASI, AAD, Safety, Abstract, Patient, Congress, LEO, Ageing, Leo Pharma, American Academy, Pharmaceutical industry

LEO Pharma A/S, a global leader in medical dermatology, today unveiled new data analyzing the long-term therapeutic response of treatment with Adbry® (tralokinumab-ldrm) in adults (18 years and above) with moderate-to-severe atopic dermatitis (AD).

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today unveiled new data analyzing the long-term therapeutic response of treatment with Adbry® (tralokinumab-ldrm) in adults (18 years and above) with moderate-to-severe atopic dermatitis (AD).
  • The findings are being shared via an e-poster at the 82nd American Academy of Dermatology (AAD) Congress in San Diego, California.1
    The results are part of a wide-ranging data program from LEO Pharma at AAD, with eight abstracts accepted in total for the meeting, showcasing an ongoing commitment to advancing the standard of research in medical dermatology.
  • “The data presented for Adbry at AAD further builds upon an established, wide-ranging collection of clinical evidence that aims to improve the support for those living with moderate-to-severe AD,” said Brian Hilberdink, EVP and President, Region North America, LEO Pharma.
  • “This new analysis demonstrates the benefits of the long-term use of Adbry for adults who live with this chronic condition.”

Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
Friday, March 8, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, JAAD, Risk, Annual general meeting, AAD, Skin, Abstract, Patient, Castle, GEP, Dermatology, American Academy, Pharmaceutical industry

In the study, use of the DecisionDx-Melanoma test was associated with improved melanoma-specific survival relative to untested patients.

Key Points: 
  • In the study, use of the DecisionDx-Melanoma test was associated with improved melanoma-specific survival relative to untested patients.
  • The study data demonstrate that clinicians are utilizing the DecisionDx-SCC test appropriately for patients with high-risk cutaneous squamous cell carcinoma (SCC).
  • These data support incorporating the test’s results into clinical practice to improve the accuracy of risk predictions to guide more personalized treatment plans for patients.
  • Approximately 80% of clinically tested lesions with a malignant MyPath result have sufficient biopsy tumor content for DecisionDx-Melanoma testing.